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Cao et al. (2015) demonstrated that the anorexic effects of mimecan are
independent from leptin and melanocortin signalling with data show-
ing a reduction in food intake still observed in obese leptin receptor
knockout mice (db/db mice) and Agouti mice (AY/a mice) respectively.
Cao et al. (2015) suggest mimecan-induced anorexia, within the central
nervous system, is probablymediated via interleukin 1β (IL-1β) and IL-
6. It is known that IL-6 production occurs selectively in microglia ratherOriginally adipose tissue was considered a site of energy storage,
the study by Cao et al. (2015) supports the emerging evidence for mi-
croglia mediated anorexic effects (Le Foll et al., 2015). Microglia and as-providing mechanical as well as heat insulation and playing a role in
the regulation of thermogenesis. However, since the discovery of Leptin
in 1994 adipose tissue is now also recognised as an endocrine organ that
produces a multitude of substances referred to as “adipokines”. These
include adipolin, adiponectin, interleukin-6 (IL-6), leptin, omentin, tu-
mour necrosis factor alpha (TNFα) and visfatin which play important
roles in the regulation of food intake and metabolism (Smitka and
Maresova, 2015). Adipose tissue is currently considered the largest en-
docrine organ secreting a multitude of hormones and cytokines known
to affect processes both within the peripheral and central nervous
system.
With respect to leptin and food regulation the adipose tissue acts as
a ‘safety valve’ controlling the long term regulation of food intake. Lep-
tin is released in proportion to the degree of adiposity and reduces food
intake when energy reserves are sufﬁcient. Unfortunately, in chronic
high fat diet induced obesity the ‘safety valve’malfunctions,with the oc-
currence of leptin resistance in the hypothalamus exacerbating the
problemof obesity (Munzberg et al., 2004). Therefore, as a central target
for the treatment of obesity, leptin and leptin analogues have proved
disappointing as possible pharmacotherapies. The study by Cao et al.
(2015) revealed that mimecan, ﬁrst identiﬁed in the organic matrix of
bovine bone, is also expressed in adipose tissue and is a potential target
for the treatment of obesity. Cao et al. (2015) described mimecan as a
satiety hormone with both intraperitoneal and intracerebroventricular
injections suppressing food intake. Information on whether this is due
to changes in meal size or meal frequency is unavailable but the
cumulative effects ofmimecan on food intake appear to be considerable.m.2015.09.044.
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lthan astrocytes and primary hypothalamic neuronal cells and therefore
trocytes may prove to be critical in appetite regulation within the
central nervous system with the potential to be new novel targets for
the treatment of obesity.
There are stillmany questions to be answered before the importance
of mimecan in food intake and appetite regulation can be determined
These include translation of ﬁndings in themouse to the human and es-
tablishment of the effectiveness of mimecan on food intake in high fat
diet induced obesity. For instance, leptin is effective at reducing food in-
take in leptin knockout mice (ob/obmice) (Halaas et al., 1995) and also
obese humans with defective leptin production (Paz-Filho et al., 2011)
It is only in diet-induced obese conditions that leptin resistance is ob-
served. It is therefore essential to establish the effectiveness ofmimecan
at reducing food intake in high fat diet induced obese mice. In addition
although the effect of mimecan on food intake is promising there ap-
pears to be desensitisation to mimecan over treatment days raising
some doubts on the usefulness of mimecan as a pharmacotherapy for
obesity.
Cao et al. (2015) reason that, as lower concentrations of mimecan
were required to elicit an anorexic effect via intracerebroventricular
compared to intraperitoneal injections, mimecan is acting centrally
They discount any possible peripheral effect. It would be useful to
know the circulating levels of mimecan after intraperitoneal injections
in addition to the clearance rates. It is known that numerous adipokines
are expressed in other peripheral regions associatedwith satiety signal-
ling, such as the gastrointestinal tract. For example, leptin is not only
expressed in adipose tissue but also the stomach where it modulates
vagal afferent satiety signals (Kentish et al., 2013). Cao et al. (2015)
demonstrated that mimecan is expressed in other organs and tissue
such as the lungs but did not look at expression in the gastrointestina
tract where the short term regulation of food intake andmeal size is ini-
tiated. Itwould be interesting to see if speciﬁc regionswithin the gastro-
intestinal tract express mimecan.
1585A.J. Page / EBioMedicine 2 (2015) 1584–1585In conclusion, mimecan is an adipokine hormone that induces an-
orexia centrally by increasing IL-1β and IL-6 in the hypothalamus. The
role mimecan plays in the regulation of food intake in high fat diet in-
duced obesity and the therapeutic potential of mimecan or analogues
of mimecan in the treatment of obesity remains to be determined.
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